Banco Bilbao Vizcaya Argentaria S.A. Grows Stock Holdings in Liquidia Corporation $LQDA

Banco Bilbao Vizcaya Argentaria S.A. grew its holdings in Liquidia Corporation (NASDAQ:LQDA) by 466.7% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 170,000 shares of the company’s stock after acquiring an additional 140,000 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A. owned about 0.20% of Liquidia worth $2,192,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the business. Hurley Capital LLC acquired a new position in Liquidia in the first quarter valued at $32,000. Quarry LP purchased a new stake in shares of Liquidia in the 1st quarter valued at about $79,000. Corsair Capital Management L.P. acquired a new stake in shares of Liquidia in the 1st quarter valued at about $148,000. Aigen Investment Management LP purchased a new position in Liquidia during the 1st quarter worth approximately $151,000. Finally, Ballentine Partners LLC increased its position in Liquidia by 10.2% during the second quarter. Ballentine Partners LLC now owns 12,139 shares of the company’s stock worth $151,000 after buying an additional 1,119 shares during the period. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Insider Transactions at Liquidia

In other Liquidia news, insider Jason Adair sold 26,057 shares of the company’s stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $27.86, for a total value of $725,948.02. Following the transaction, the insider directly owned 171,029 shares of the company’s stock, valued at $4,764,867.94. This represents a 13.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Roger Jeffs sold 20,261 shares of the company’s stock in a transaction that occurred on Monday, October 13th. The shares were sold at an average price of $23.41, for a total value of $474,310.01. Following the completion of the transaction, the chief executive officer directly owned 1,032,973 shares of the company’s stock, valued at approximately $24,181,897.93. This trade represents a 1.92% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 920,522 shares of company stock worth $25,512,207. 30.10% of the stock is owned by company insiders.

Liquidia Stock Up 4.1%

LQDA stock opened at $28.04 on Monday. The company has a debt-to-equity ratio of 6.19, a current ratio of 2.20 and a quick ratio of 1.96. The firm has a fifty day moving average price of $24.40 and a two-hundred day moving average price of $20.36. Liquidia Corporation has a 1-year low of $9.71 and a 1-year high of $29.94. The firm has a market cap of $2.44 billion, a price-to-earnings ratio of -19.47 and a beta of 0.12.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.41. The business had revenue of $54.34 million for the quarter, compared to analyst estimates of $18.86 million. Liquidia had a negative net margin of 176.04% and a negative return on equity of 296.78%. The company’s quarterly revenue was up 1106.7% compared to the same quarter last year. Research analysts predict that Liquidia Corporation will post -1.51 EPS for the current year.

Analyst Ratings Changes

Several brokerages have issued reports on LQDA. HC Wainwright raised their price objective on shares of Liquidia from $35.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a research report on Wednesday, October 8th. Needham & Company LLC increased their price objective on Liquidia from $36.00 to $52.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Raymond James Financial reiterated a “strong-buy” rating and issued a $47.00 target price on shares of Liquidia in a research note on Tuesday, November 4th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $45.00 price target on shares of Liquidia in a research note on Monday, November 3rd. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $38.56.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).